Asciminib (Scemblix)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Asciminib (Scemblix), covering 2024-07-23 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. [Phase 2]